Next, the cytotoxicity of activated NK cells in combination with pembrolizumab was analysed in vitro against HCT-116, HT-29, and DLD-1 CRC cell lines (Figure 6A), which showed differences in PD-L1 expression. The gene discussed is CD274; the disease is colorectal carcinoma.